High density lipoprotein and lipoprotein oxidation

Current Opinion in Lipidology

Volumn 7, Issue 3, 1996, Pages 139-142

  Banka, Carole L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; HUMAN; HYDROLYSIS; LIPID OXIDATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0030057184     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199606000-00005     Document Type: Short Survey

References (43)

1. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1792.
2. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995, 91:2488-2496.
3. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Jacobs JD Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardio-vascular disease. Circulation 1989, 79:8-15.
4. Pieters MN, Schouten D, Van Berkel TJC: In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994, 1225:125-134.
5. Hessler JR, Robertson AL Jr, Chisolm GM: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979, 32:213-229.
6. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990, 1044:275-283.
7. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039-2046.
8. Tall AR: Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990, 86:379-384.
9. Sakai M, Miyazaki A, Hakamata H, Sasaki T, Yui S, Yamazaki M, Shichiri M, Horiuchi S Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 1994, 269:31430-31435. The importance of lysophosphatidylcholine in the mitogenic effect of oxLDL on macrophages was described. The inhibition of the mitogenic effect by HDL was accompanied by a loss of lysophosphatidylcholine in the oxLDL. Apoprotein A-I alone had no inhibitory activity. However, lysophosphatidylcholine vesicles alone did not inhibit to the same extent as oxLDL, suggesting that HDL inhibition of mitogenesis relies on an additional, as yet unknown, mechanism.
10. Matsuda YK, Hirata K, Inoue N, Suematsu M, Kawashima S, Akita H, Yokoyama M High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 1993, 72:1103-1109.
11. Galle J, Sengen J, Schollmeyer P, Wanner C: Oxidized lipoprotein(a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein. Eur J Pharmacol 1994, 265:111-115. Oxidized lipoprotein(a) from the same donor and modified by the same protocol as LDL is a more potent inhibitor than oxLDL of vasodilation in endothelium-intact isolated rabbit renal arteries. Inclusion of HDL in the perfusion system completely abolishes the inhibitory effect of oxidized lipoprotein(a). Several mechanisms for the HDL protection are presented but not tested.
12. Klimov AN, Gurevich VS, Nikiforova AA, Shatilina LV, Kuzmin AA, Plavinsky SL, Teryukova NP: Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis 1993, 100:13-18.
13. Kunitake ST, Jarvis MR, Hamilton RL, Kane JP: Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. Proc Natl Acad Sci USA 1992, 89: 6993-6997.
14. Ehrenwald E, Chisolm GM, Fox PL: Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994, 93: 1493-1501.
15. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cultures. J Clin Invest 1995, 96:2758-2767. Acute phase HDL from humans and rabbits is characterized by increases in apoprotein A-I, ceruloplasmin and serum amyloid A, and decreases in paraoxonase and PAF-AH. Inclusion of acute phase HDL with LDL in aortic wall cocultures leads to increases in synthesis of monocyte chemotactic protein-1 and monocyte binding to endothelial cells. Acute phase HDL appears to be proinflammatory.
16. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM: Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 1991, 266:11095-11103.
17. Stafforini DM, McIntyre TM, Carter ME, Prescott SM: Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987, 262:4215-4222.
18. Tselepis AD, Dentan C, Karabina SAP Chapman MJ, Ninio E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma-catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vase Biol 1995, 15:1764-1773.
19. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM: The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Amer Assoc Phys 1993, 106:44-63.
20. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J clin Invest 1995, 95:774-782. Minimally modified LDL and biologically active lipids isolated from modified LDL are inactivated by treatment with PAF-AH. A serine esterase inhibitor inactivates PAF-AH in LDL and HDL and enhances oxidative modification of the LDL, whereas HDL looses its protective characteristics. Replenishing LDL and HDL with PAF-AH inhibits monocyte binding to endothelial cells.
21. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995, 96:2322-2330. A PAF-like lipid in oxLDL stimulates smooth muscle cell growth. The smooth muscle cell growth is abolished by platelet-activating factor receptor agonists and PAF-AH. The possibility that the smooth muscle cell effects are mediated by lysophosphatidylcholine was convincingly ruled out.
22. Mackness MI, Walker CH: Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. Biochem J 1988. 250:539-545.
23. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF. Fogelman AM: Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995, 96:2882-2891. Paraoxonase inactivates biologically active oxidized phospholipids isolated from modified LDL and contributes to the antioxidant protection conferred by HDL on LDL. Paraoxonase hydrolyzes long chain phospholipids. The contributions of paraoxonase and PAF-AH to the HDL inhibition of LDL oxidation are additive.
24. Mackness MI, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286: 152-154.
25. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
26. Bowry VW, Stanley KK, Stocker R: High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992, 89:10316-10320.
27. Sattler W, Stocker R: Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. Biochem J 1993, 294:771-778.
28. Christison JK, Rye KA, Stocker R: Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995, 36:2017-2026. Cholesteryl ester transfer protein mediates bidirectional transfer of cholesteryl ester hydroperoxides and hydroxides between HDL and LDL to the same extent as non-oxidized cholesteryl esters. The direction and rate of transfer is dependent upon molar ratios of HDL and LDL. Cholesteryl ester hydroperoxides associated with HDL are more rapidly reduced to the less reactive hydroxides than those associated with LDL.
29. Sattler W, Christison J, Stocker R: Cholesterylester hydroperoxide reducing activity associated with high- and low-density lipoproteins. Free Radic Biol Med 1995, 18:421-429. A putative lipid hydroperoxide reductase activity is characterized and found to be associated exclusively with intact lipoproteins, independent of transition metals, temperature dependent, and significantly more active in HDL. This suggests that a lipoprotein-associated cholesteryl ester hydroperoxide reductase contributes to the protective function of HDL.
30. Hahn M, Subbiah MTR: Significant association of lipid peroxidation products with high density lipoproteins. Biochem Mol Biol Int 1994, 33: 699-704.
31. Suzukawa M, Ishikawa T, Yoshida H, Nakamura H: Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification. J Am Coll Nutr 1995, 14:46-52.
32. Frei B, Forte TM, Ames BN, Cross CE: Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 1991, 277:133-138.
33. Francis GA, Mendez AJ, Bierman EL, Heinecke JW: Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc Natl Acad Sci USA 1993, 90:6631-6635.
34. Marcel YL, Jewer D, Leblond L, Weech PK, Milne RW: Lipid peroxidation changes the expression of specific epitopes of apolipoprotein A-I. J Biol Chem 1989, 264:19942-19950.
35. Nagano Y, Arai H, Kita T: High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991, 88:6457-6461.
36. 2+-mediated oxidation. FEBS Lett 1992, 314:199-202.
37. Salmon S, Maziere C, Auclair M, Theron L, Santus R, Maziere JC: Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human-cultured fibroblasts. Biochim Biophys Acta 1992, 1125:230-235.
38. Morel DW: Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Commun 1994, 200:408-416.
39. Guertin F, Brunet S, Gavino V, Tuchweber B. Levy E: Malondialdehyde-modified high-density lipoprotein cholesterol: plasma removal, tissue distritubion and biliary sterol secretion in rats. Biochim Biophys Acta Lipids Lipid Metab 1994, 1214:137-142.
40. McCall MR, Tang JY, Bielicki JK, Forte TM: Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vase Biol 1995, 15:1599-1606. Incubation of human plasma with aldehydes known to be products of lipid peroxidation results in cross-linking of HDL apoproteins and decreased lecithin: cholesterol acyltransferase activity.
41. 3 in rat Biochim Biophys Acta 1990, 1046:81-88.
42. Traber MG, Ingold KU, Burton GW, Kayden HJ: Absorption and transport of deuterium-substituted 2R,4′R,8′R-a-tocopherol in human lipoproteins. Lipids 1988, 23:791-797.
43. Rifici VA, Khachadurian AK: The inhibition of low-density lipoprotein oxidation by 17-β estradiol. Metabolism 1992, 41:1110-1114.